339 Results
Sort By:
Published on January 20, 2017
Interpace Diagnostics said today that Best Med Opinion will be the exclusive provider of its molecular diagnostic tests for Israel, through a partnership that will promote Interpace’s tests to physicians and patients. The partnership covers Interpace’s three marketed tests: ThyGenX and ThyraMIR, both designed to determine the presence and absence…
Published on January 4, 2017
Interpace Diagnostics has joined the Blue Cross Blue Shield (BCBS) Association's Center for Clinical Effectiveness’ “Evidence Street” program, enabling the cancer-focused molecular diagnostics developer to present evidence designed to support future coverage decisions for its thyroid and pancreas diagnostic tests. Under an agreement announced Tuesday, Interpace said it will work…
Published on June 20, 2016
Under a new research agreement, Takeda Pharmaceuticals and healthcare informatics company M2Gen will use data generated by the Oncology Research Information Exchange Network (ORIEN) to map and better understand the genetic profiles of patients with a range of cancers, all with the intent of speeding development work of new cancer…
Published on May 27, 2015
Halozyme Therapeutics said today it will co-develop a companion diagnostic for its cancer drug candidate PEGPH20 with Ventana Medical Systems, a member of the Roche Group. The value of the collaboration was not disclosed. Ventana will ultimately commercialize the in vitro diagnostic, an assay designed to identify high levels of…
Published on September 30, 2024
Testing firm Genialis has announced the commercial availability of its krasID test, which it calls: “the first biomarker algorithm that predicts patient response and clinical benefit to KRAS inhibitors (KRASi) across tissue histology and mutation type.” Genialis’s krasID was developed to help guide drug development from early preclinical phases, to…
Published on August 12, 2024
When it comes to studying and treating cancer, scientists and clinicians often think of applying two key areas of knowledge: the immune system and genomics. The combination of those fields—immunogenomics—is not quite a new field, but it is on the rise. Even in 2015, Robert Holt, PhD, scientific co-director of…
Published on April 8, 2024
Enhertu (AstraZeneca and Daiichi Sankyo’s trastuzumab deruxtecan) has become the first tumor-agnostic, FDA-approved, HER2-directed therapy. It is approved for adult patients with unresectable or metastatic HER2-positive (IHC 3+) solid tumors. Enhertu is an antibody drug conjugate (ADC) that consists of a HER2 monoclonal antibody attached to a number of topoisomerase…
Published on August 8, 2023
Astellas and Poseida Therapeutics have announced a deal around Poseida’s MUC1C-ALLO1, an allogeneic CAR-T cell therapy in Phase I for multiple solid tumor indications. Astellas will invest a total of $50 million, including $25 million to acquire shares of common stock of Poseida at $3.00 per share in a private…
Published on February 15, 2023
CD70 is highly expressed on drug-resistant cancer cells in EGFR-mutant non-small cell lung cancer (NSCLC) representing a promising new target for treatment of cancer cells that remain after a patient receives EGFR tyrosine kinase inhibitor (TKI) therapy. The new research from investigators at The University of Texas MD Anderson Cancer…
Published on December 2, 2022
A ketogenic diet very low in carbohydrates can counteract the reduced blood platelet counts that often result from chemotherapy, a study in mice and men suggests. The findings, which appear in Science Translational Medicine, add to the potential therapeutic benefits of this diet, which is already being used for epilepsy…
Published on November 16, 2022
Underprivileged children who receive CAR T-cell therapy for acute lymphoblastic leukemia (ALL) have similar outcomes as those from more advantaged households, according to a new study published in Blood. This is particularly surprising since, overall, children with ALL living in poverty are significantly more likely to relapse and die from…
Published on November 8, 2022
In 2016, in an effort to better focus business priorities, Fulgent Therapeutics separated into pure-play diagnostics and therapeutics companies Fulgent Genetics and Fulgent Pharma. Yesterday, after six years of honing their business models, publicly traded Fulgent Genetics announced it was acquiring Fulgent Pharma for $100 million to create a vertically…
Published on October 27, 2022
Candel Therapeutics, a clinical stage developer of viral immunotherapies, announced Wednesday that it will collaborate with researchers at the University of Pennsylvania’s (UPenn) Center for Cellular Immunotherapies to study the efficacy of using viral immunotherapies to help boost the effects of UPenn’s CAR-T cell therapies in solid tumor models. The…
Published on October 21, 2022
HOOKIPA Pharma has announced a strategic collaboration and license agreement with Roche to develop its HB-700 immunotherapy for KRAS-mutated cancers and a second undisclosed drug. This is HOOKIPA’s first oncology licensing collaboration. The company is developing a new class of immunotherapies based on its proprietary replicating arenavirus platform. HOOKIPA will…
Published on June 29, 2022
Researchers at the University of Chicago observed the role of beta cells in triggering autoimmunity, and found that knocking out a proinflammatory gene in the beta cells of mice genetically predisposed to develop T1D preserved beta cell mass and protected the animals from developing diabetes. The research findings also raise…